News Archive | Page 5 of 10 | Breakthrough T1D

JDRF Canada Sets Out to Make History Again

March 10, 2022

MEDIA RELEASE

As Canada Marks 100th Anniversary of First Successful Injection of Insulin, JDRF Canada Sets Out to Make History Again

Five Brave Canadian Volunteers Set to Live Atop a Flagpole for 100 Hours, Raising Funds to Find a Cure for Type 1 Diabetes

TORONTO, March 10, 2022 — JDRF Canada, the largest charitable funder of type 1 diabetes (T1D) research in the country, is publicly launching its largest-ever fundraising campaign, the $100M Campaign to Accelerate. The campaign aims to accelerate the pace of T1D research being done in Canada to help find a cure. Canada discovered insulin and by supporting research, Canada can cure diabetes.

To make history again, five brave Canadians impacted by T1D will live atop a 40-foot flagpole in cities across the country as part of JDRF’s Let’s Make History Again event. They will do this for 100 hours this spring, beginning on April 4, to help raise $15 million to help find a cure for T1D.

The Let’s Make History Again event honours the anniversaries of the discovery of insulin and the first successful injection of insulin—both of which took place in Toronto 100 years ago— while accelerating research to move beyond insulin and find a cure. The event features the Flagpole 100 challenge, which was inspired by Oliver & Bonacini Co-Founder and longtime JDRF supporter, Peter Oliver, who—32 years ago—lived atop a flagpole until he raised $250,000 for T1D research after his daughter’s diagnosis at the age of six. He attributed the inspiration for the flagpole to the endless balancing act of life and death decisions that those living with T1D face each day, which can feel extremely isolating, similar to being alone atop a flagpole.

“I still remember getting the call when my daughter Vanessa was first diagnosed at the age of six. We didn’t know a thing about diabetes, but Vanessa thought the ‘di’ in ‘diabetes’ meant you were going to die,” says Peter Oliver. “That day has stuck with me my whole life. I think of all the families and children that experience that same moment and I strongly believe when there is a cure for diabetes, it will go down as one of the greatest achievements in the history of mankind.”

When insulin was discovered 100 years ago in Toronto, Canada, researchers Frederick Banting and Charles Best sold its patent for only $1. It was considered one of Canada’s greatest gifts to the world, however those living with T1D still require insulin to stay alive.

“Let’s Make History Again is truly a rallying cry for all Canadians who have been impacted by diabetes,” says Dave Prowten, President and CEO of JDRF Canada. “While the discovery of insulin in Canada 100 years ago has saved millions of lives, it is still only a treatment and not a cure. It is fitting that now is the time to map out the next era of discovery in type 1 diabetes research. Not only will this propel us forward in finding a cure for the disease, but it’s incredibly inspiring to see so many Canadians and families galvanized by this cause that touches the lives of so many.”

“With the help of the JDRF, researchers like myself are driving innovative research with the goal of improving strategies to treat or prevent T1D,” says Dr. Patrick MacDonald, Professor of Pharmacology at the University of Alberta. Dr. MacDonald’s JDRF-funded work aims to develop a comprehensive molecular encyclopedia about insulin-producing islet cells to uncover new approaches to improve glucose regulation as well as inform ongoing and future T1D cure research.

The five Leaders in History will unite atop 40-foot flagpoles in cities across the country for 100 hours to help raise $15 million for JDRF’s $100M Campaign to Accelerate from April 4 until April 8, 2022. The Leaders in History will head atop the flagpoles on April 4 at 11 a.m. local time and the public is welcome to stop by and show their support.

Flagpoles will be located at:
• Toronto-Dominion Centre, 55 King St W, Toronto, ON M5H 3C2
• UHN (Toronto General Hospital), 585 University Ave., Toronto, ON M5G 2C4
• 200 Granville Street, Vancouver, BC V6C 1S4
• Calgary City Centre, 215 2 St SW, Calgary, AB T2P 0H7
• Rio Tinto Indoor Courtyard 1160 Av. des Canadiens-de-Montréal, Montréal, QC H3B 2S2

Camping in solidarity with our Leaders in History will be our 100 Ambassadors of History families. These families will be camping in their local parks, backyards or even their basements, undertaking the challenge to support JDRF and raise funds to find a cure for T1D.

To get involved and make a lasting impact on the future of T1D research and care, JDRF invites Canadians to become History Makers. You can help JDRF make history again by registering and joining hundreds of people across the country who will be doing their own unique challenge to raising funds and awareness for JDRF. To learn more about getting involved visit canadacuresdiabetes.ca.

Some words from some of the JDRF’s incredible partners:

“It’s an honour to celebrate this remarkable achievement and help mark the 100th anniversary of the discovery and first successful injection of insulin in this country,” said Susan O’Brien, Chief Brand and Customer Officer, Canadian Tire Corporation. “As we celebrate our own 100th anniversary this year, we continue our longstanding commitment to making life in Canada better. We’re proud to partner with JDRF’s Let’s Make History Again initiative and commit $500,000 through a combination of financial support and in-kind donations to help find a cure for those living with type 1 diabetes.”

“At Cadillac Fairview, we have a strong legacy of supporting our communities, clients and partners and the causes that are important to them to inspire meaningful change,” said Sal Iacono, Executive Vice President of Operations, Cadillac Fairview. “This year’s centennial milestone event is an incredible accomplishment in the fight against type 1 diabetes and we’re proud to support the campaign by hosting the Flagpole 100 Challenge at four CF office towers across Canada and making a donation to support ongoing research. Together, alongside our longtime partner, Oliver & Bonacini, we are excited to make history with JDRF.”

“We are thrilled to see the enthusiasm and efforts of our employees and volunteers who have come together around the JDRF Flagpole 100 Challenge. The Walters Group family is passionate about making a difference!”, says Peter Kranendonk, Chief Executive Officer of Walters Group. “Building History is our purpose and this transformational campaign inspired us because we care about every fellow Canadian who struggles with or is affected by type 1 diabetes. These structures are being built with our hearts and our hands in the hope and with the prayer that all of us together will Make History Again with great therapies and a cure for T1D!”

“For more than 20 years, Dexcom’s singular focus has been to give people the power to change how they live with diabetes through our CGM technology. We are so excited to be partnering with JDRF Canada as they make history with the Flagpole 100 Challenge,” said Laura Endres, Senior Vice President and General Manager of Dexcom Canada. “One day there will be a cure for diabetes, but until then, we will work every day to empower people to take control of their diabetes and live life to the fullest.”

“We are so proud of our partnership with JDRF and Lilly was beyond excited to support a campaign acknowledging one hundred years of discovery, while inspiring Canadians to persist in our collective effort to beat diabetes,” says Rhonda Pacheco, General Manager, Lilly Canada “At PCL, we’re driven to build a better future by building people, communities and legacies. We are proud to contribute to JDRF through supporting and building the flagpoles to help commemorate the 100th anniversary of the discovery of insulin. We hope that through the combined efforts of all those involved, we can do our part to support JDRF’s mission of improving lives for those living with type 1 diabetes.” Mike Wieninger, Chief Operating Officer, Canadian Operations for PCL Construction

About JDRF

JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested more than $3 billion CAD in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, governments, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout Canada and six international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit breakthrought1d.ca.

###

For further information please contact Laura Gannon at laura@pomppr.com.

In Memoriam

March 9, 2022

We are deeply saddened by the sudden passing of Andrew McKee, former President and CEO of JDRF Canada. Andrew began his journey with JDRF Canada as a Board member. His passion and dedication led him to assume the role of President and CEO for several years. Through his leadership, he blazed an exciting trail for our organization. Andrew was deeply committed to JDRF and the type 1 diabetes (T1D) community and was the driving force behind the creation of the JDRF Canadian Clinical Trial Network, which is an incredible partnership with our federal government and JDRFI. His legacy lives on through the research that was done by this network in Canada and around the world, and will continue to benefit people for years to come.

We extend our deepest condolences to his family and friends at this difficult time, and are grateful for his unwavering service to JDRF and the T1D community.

https://humphreymiles.com/tribute/details/6542/John-McKee/obituary.html#tribute-start

Ontario announces coverage for continuous glucose monitoring systems under the Assistive Devices Program

March 4, 2022

Friday, March 4, 2022 Toronto, ON – Today, the Ontario government made an exciting announcement that will provide better access for Ontarians with type 1 diabetes (T1D) to continuous glucose monitoring (CGM) systems. These devices will be covered under Ontario’s Assistive Devices Program (ADP), which also provides coverage for insulin pumps. ADP is available to Ontario residents who have a valid Ontario health card and can demonstrate that they have a condition requiring the equipment or supplies for six months or longer.

“JDRF Canada is thrilled that Ontario will provide coverage for CGM devices to those living with type 1 diabetes. These technologies are critical in preventing life-threatening complications and improving health outcomes, while also providing rich data to clinicians, as we continue to rely on virtual care. Those living with type 1 diabetes in Ontario can now lead healthier, safer, and easier lives until a cure is found,” says Dave Prowten, President and CEO, JDRF Canada.

T1D self-management is made easier through technologies such as CGMs which provide real-time readings that help to improve overall blood glucose (HbA1C) and time in target range (TIR) keeping more people out of hospital, and reducing longer-term complications. Better self-management and glucose control also helps to relieve some of the anxiety that surrounds the disease. It allows people with T1D to better plan exercise, meals, and rest. Universal coverage of CGM would increase the number of people living free of complications by an estimated 7,400 and decrease mortality by an estimated 11,500.

“In the absence of government support, people living with diabetes will continue to pay out of pocket to manage the rising, additional costs. This could be upwards of $15,000 per year for one individual and will only increase the divide between those who can and those who cannot afford these technologies,” adds Prowten.

In the past three years, there has been significant commitments from six provincial and territorial governments to improve access to diabetes technology. In Ontario, public coverage is available for both CGM and Flash GM. We applaud the government for recognizing the clear evidence of both the cost-benefit and quality of life outcomes these devices undeniably provide.

JDRF welcomes today’s announcement from the Ontario government after ongoing advocacy efforts through the Access for All campaign to educate and inform decisionmakers of the benefits of funding these technologies. JDRF believes that patient choice is paramount to better T1D management. The organization will continue to advocate until there is universal access to advanced glucose monitoring devices and insulin pumps for all Canadians living with T1D.

To learn more about JDRF’s #AccessForAll campaign visit: www.breakthrought1d.ca/accessforall

For more information on the Assistive Devices Program, visit: https://www.ontario.ca/page/assistive-devices-program

Helping the diabetes community in Ukraine

March 3, 2022

Please see this link to read the JDRF International statement on the ongoing crisis in Ukraine.

JDRF in the United States joining partners to support new affordable insulin project with a focus on the US market.

March 3, 2022

March 3, 2022 – Statement by Dave Prowten, President and CEO, JDRF Canada

JDRF has long supported both public and private sector initiatives to make insulin more affordable to ensure people with type 1 diabetes (T1D) can access the insulin they need to stay alive and healthy until we have cures.

Today, just two days after U.S. President Biden’s State of the Union address declared, “let’s cap the cost of insulin at $35 a month so everyone can afford it,” JDRF in the U.S., in partnership with a myriad of other health organizations, is announcing a new partnership with Civica Inc. (Civica Rx, Civica), a non-profit generic drug company. This innovative partnership will facilitate bringing a low-cost biosimilar insulin option to Americans at $30 per vial and $55 per box of 5 pens starting in 2024. As it is common for a vial of insulin in the United States to cost as much as $300USD – a significant barrier to care – more affordable access to low-cost insulin, the life-saving therapy anyone living with T1D requires, is essential.

In Canada, a vial of insulin costs on average between $30-$40CAD, with more than 90 per cent of those costs covered by some form of public or private insurance. These costs are regulated by the Patented Medicines Prices Review Board (PMPRB) which limits the prices set by patentees for all patented medicines to ensure they are not excessive. In addition, the pan-Canadian Pharmaceutical Alliance (pCPA) works to negotiate directly with manufacturers to increase access to lower-cost drugs in Canada. With this regulatory process in place, and with the cost of insulin in Canada being exponentially lower than the United States, the initiative with Civica Inc. is not anticipated to expand here.

Anyone requiring life-sustaining therapy, such as those living with T1D, should never be unable to access or afford the treatments that keep them alive – like insulin. As a global charity, JDRF encourages countries to work collaboratively with all stakeholders to find ways to keep drug costs down worldwide.

JDRF Canada remains a strong advocate for the affordability and accessibility of all appropriate treatments, services, devices and medications (including insulin). As we know, anyone living with T1D requires insulin to stay alive. However, when that treatment is coupled with devices such as insulin pumps and advanced glucose monitors (CGM and Flash GM), self-management and health outcomes can significantly improve. Unfortunately, there are accessibility challenges with these devices due to limited coverage, as well as variability of public and private coverage, which leads to continued high out-of-pocket costs for many Canadians living with diabetes.

That is why JDRF Canada continues to advocate through our Access for All campaign to make T1D technology affordable and accessible for everyone living with this disease. Since its launch, thousands of Canadians have been able to access these technologies as provincial and territorial governments agree on the cost-benefit and quality of life outcomes these devices undeniably provide. JDRF continues to support the efforts of the T1D community so that equitable access to these life-saving technologies can be guaranteed across the country. To join our efforts, visit https://breakthrought1d.ca/advocacy/access-for-all/.

Alberta announces new coverage for continuous glucose monitoring (CGM) systems

February 2, 2022

Wednesday February 2, 2022 – JDRF Canada is excited to share that the Alberta government has announced that they will provide public coverage for continuous glucose monitoring (CGM) systems for people with type 1 diabetes (T1D) who are under the age of 18. To qualify, individuals must be enrolled in the province’s non-group coverage or satisfy a means test to demonstrate low-income.

“We applaud the Alberta government’s decision to provide CGM devices to those living with type 1 diabetes who are under 18. We encourage the government’s ongoing expansion of the age of eligibility for these live-saving devices for Albertans living with T1D” says Dave Prowten, President and CEO, JDRF Canada.

T1D self-management is made easier through technologies such as CGMs which provide real-time readings that help to improve overall blood glucose (HbA1C) and time in target range (TIR), keeping more people out of hospital, and reducing longer-term complications. Better self-management and glucose control also helps to relieve some of the anxiety that surrounds the disease. It allows people with T1D to better plan exercise, meals, and rest. Universal coverage of CGM would increase the number of people living free of complications by an estimated 7,400 and decrease mortality by an estimated 11,500.

“Patient choice continues to be a priority for JDRF’s Access for All campaign. T1D is a complex disease that affects people very differently, so we hope that in the future, the Flash GM will be covered in Alberta as well. It is important that patients, in consultation with their health care providers, decide on their best course of treatment, and not be limited simply due to what is covered” adds Prowten.

Since JDRF launched its Access for All campaign in 2019, we have seen significant commitment from provincial and territorial governments to improve access due to the cost-benefit and quality of life outcomes these devices undeniably provide. We laud the Alberta government for recognizing this need, and welcome today’s announcement as another win for the T1D community.

JDRF also credits the efforts of JDRF’s incredible advocacy volunteers who make up the Alberta provincial advisory group for helping raise awareness through the Access for All campaign about the need for provincial coverage by educating and informing decisionmakers of the benefits of funding these technologies. JDRF believes that patient choice is paramount to better T1D management. The organization will continue to advocate until there is universal access to advanced glucose monitoring devices and insulin pumps for all Canadians living with T1D.

To learn more about JDRF’s #AccessForAll campaign visit: www.breakthrought1d.ca/accessforall

JDRF Canada’s First Centre of Excellence in Type 1 Diabetes Research Launches at the University of British Columbia

December 8, 2021

Toronto, ON — December 8, 2021 – JDRF Canada, the largest Canadian charitable funder of type 1 diabetes (T1D) research, and the UBC Faculty of Medicine are proud to announce the establishment of Canada’s first JDRF Centre of Excellence in T1D research at the University of British Columbia.

Exclusively focused on research to cure T1D, the Centre is a key pillar of JDRF Canada’s $100M Campaign to Accelerate that launched earlier this year and is among only five such Centres worldwide. A $10M fundraising campaign is currently underway to support the Centre, and with more than fifty percent already raised, an ambitious research program has begun.

JDRF Centres of Excellence – Established to Fuel Discovery

JDRF Centres of Excellence provide a research funding model that fosters highly dynamic and nimble work to drive discovery with maximum speed. In contrast to conventional research granting mechanisms, a Centre of Excellence adopts a highly collaborative approach that brings together a large team of experts from diverse fields and recruits new talent to accelerate T1D advances. This allows researchers to drive multiple projects in parallel, pivot quickly to the most promising research, yet remain focused on a unified goal of a cure for T1D.

This model is extremely cost-effective because it leverages and streamlines existing research facilities and talent. By removing the capital costs of developing a new physical space, the Centre of Excellence model ensures that philanthropic investment is directed to research rather than overhead. In line with its cure-focused global research strategy, JDRF maintains a 360-degree view of the work at all its Centres to prioritize the science that holds the most promise for the T1D community.

The JDRF Centre of Excellence at UBC

The JDRF Centre of Excellence at UBC is rooted in collaboration, uniting the expertise of world-leading UBC researchers and partnerships with industry, health care, government and academia for a singular purpose: curing T1D. The Centre will foster rapid progress and efficient translation of discoveries in the lab to clinical solutions for Canadians living with T1D.

The goal of the Centre’s research team is to bring two or more new solutions to cure or slow the progression of T1D to the clinical testing stage within just five years. Five research leads and more than 35 other researchers, trainees, technical staff and collaborators will be involved in driving the Centre’s research projects.

JDRF would like to acknowledge our campaign co-chairs Rob Fiorvento and Dan Miller, as well as our campaign cabinet members Kim Lucas, Mary Jane Devine and Michelle Tice, for their leadership and vision.

We would also like to recognize and thank several donors who have made leadership gifts that brought the Centre to reality: Joseph and Rosalie Segal, Wendy Benyk and Ray Maher, Jim Pattison, and the WB Family Foundation.

Dave Prowten, President and CEO JDRF Canada:

“The JDRF Centre of Excellence is a unique model that will develop and define new ways of moving research forward and will cultivate future leaders in type 1 diabetes (T1D) research. We are extremely excited to partner with this exceptional team because they bring multi-faceted expertise to accelerate the integrated study of the immune system and beta cells and their complex interactions – which we are confident will fuel the path towards a cure.”

Dr. Dermot Kelleher, Dean of the Faculty of Medicine and Vice-President of Health, UBC:

“Launching Canada’s first JDRF Centre of Excellence at UBC’s Faculty of Medicine is a meaningful opportunity for collaboration that will accelerate discovery and innovation toward a cure for type 1 diabetes. Our shared vision to prioritize team science will speed up the development of accessible immune therapies that alleviate dependence on insulin and ultimately improve health outcomes for patients with type 1 diabetes.”

Dr. Bruce Verchere, BC Children’s Hospital Research Institute, Professor, Faculty of Medicine UBC and Director, Centre for Molecular Medicine and Therapeutics and Irving K Barber Chair in Diabetes Research:

“The JDRF Centre of Excellence at UBC will transform T1D research in Canada, sparking new collaborations, removing barriers, and accelerating progress toward a cure. I am tremendously proud to be working alongside my Centre co-leads; Drs. James Johnson, Megan Levings, Francis Lynn and JDRF’s Dr. Sarah Linklater, to put an end to T1D within our sights.”

About JDRF

JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our goal is to raise funds to support the most advanced international T1D research and progressively remove the impact of this disease from people’s lives – until we achieve a world without it. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure T1D. For more information, please visit j drf.c a.

About UBC’s Faculty of Medicine

Ranked among the world’s top medical schools with the fifth-largest MD enrollment in North America, the UBC Faculty of Medicine is a leader in both the science and the practice of medicine. Guided by our vision—to transform health for everyone—our faculty members, learners, staff and alumni are accelerating discovery and creating pathways to better health for communities at home and around the world. Through collaboration with our partners, we strive to meet the demands of today and tomorrow, bringing real and lasting hope to people everywhere. For more information, visit med.ubc.ca or follow us on Twitter @UBCmedicine.

Media contacts:

Michelle Van Vliet
National Director, Marketing and Communications
JDRF Canada
647.459.7881
mvanvliet@jdrf.ca

Brett Goldhawk
Communications and Media Relations Manager
UBC Faculty of Medicine
778-952-7858
brett.goldhawk@ubc.ca

JDRF and CIHR Announce Recipients of New Grants to Accelerate Type 1 Diabetes Research

November 25, 2021

To mark November’s National Diabetes Awareness Month, JDRF is excited to announce a new investment of $7 million to support four Canadian research teams as part of the JDRF-CIHR Partnership to Defeat Diabetes. These grants will help to accelerate development of stem cell-based therapies for type 1 diabetes (T1D), improve pediatric diabetes research across Canada, as well as our understanding of variations in human insulin production.

This funding announcement is part of the Team Grants in Diabetes Mechanisms and Translational Solutions competition announced by CIHR, an investment of $20M in 10 research projects. Diabetes Canada, Kidney Foundation of Canada, and the FRQS have also received funding as part of this competition, as all work together to improve health outcomes for Canadians.

The funded researchers, including those funded through the JDRF-CIHR Partnership to Defeat Diabetes will work to develop new approaches to preventing, treating, and delivering care to people living with diabetes. Researchers will also work with patient partners—people with lived experience of diabetes—to ensure that the research being conducted is relevant and valuable to the people and families who are affected.

JDRF is matching the $3.5 million investment from CIHR for a total of $7 million to fund four research teams – doubling the impact on T1D research. As we honour the 100th anniversary of the discovery of insulin, this investment will help fuel promising research that will move us beyond insulin towards cures.

“JDRF is proud to partner with CIHR to accelerate research into a cure for type 1 diabetes (T1D). This year we commemorate 100 years of insulin and recognize the need to move beyond insulin therapy for as many as 300,000 Canadians currently living with T1D. This research will reduce the impact and burden on people affected by the disease, and help us achieve our ultimate goal, a world free from T1D. We are grateful to our community and donors for enabling our $3.5 million investment that will be matched by CIHR to help us attain this goal.”

– Dave Prowten, President and CEO, JDRF Canada

The JDRF-CIHR Partnership to Defeat Diabetes is a landmark collaboration between the Government of Canada, through CIHR, that began in 2017 with a $15M investment that was matched by JDRF to support transformative T1D research. This unique partnership ensures that T1D remains a priority in Canadian health research and is based on a shared vision of improved care, treatment, outcomes and cures for those living with the disease.

Since its inception, this partnership has funded several innovative clinical trials and translational research projects with a view to accelerating the development of novel treatment approaches for people with T1D, in addition to cures for the disease.

These new cutting-edge projects promise to further push forward JDRF’s mission of improving lives and finding cures.

A deep phenotyping network for understanding human islet variation in health and diabetes

Dr. Patrick MacDonald, Nominated Principal Investigator: Canada Research Chair; University of Alberta, along with his team: Dr. James D. Johnson, (University of British Columbia) Dr. Jennifer Bruin, (Carleton University) and Dr. Jianguo (Jeff) Xia, (McGill University).

Summary

Insulin is the primary hormone responsible for controlling blood sugar levels. It is produced by the pancreatic islets of Langerhans, rises after a meal to promote energy storage, and falls during fasting to allow energy mobilization. The levels of insulin in the blood vary tremendously amongst people. Nutrition, age, sex, genetics, and environmental exposures are all important factors likely to impact insulin levels. However, the underlying mechanisms by which these factors affect islet insulin production at the cellular level are not clear.

This team seeks to understand the variability in human islet function in relation to genetic and environmental impacts on diabetes risk and to identify mechanisms of islet dysfunction in diabetes. To do this they will take advantage of extensive data on the molecular, cellular, and physiological function of islets from human organ donors. They will also produce tools and resources so that other researchers can explore this data to answer their own questions about islet dysfunction in diabetes.

Building CAPACIty for pediatric diabetes research and quality improvement across Canada

Dr. Shazhan Amed, Nominated Principal Investigator: B.C Children’s Hospital, along with her team:
Dr. Meranda Nakhla, (Montreal Children’s Hospital; McGill University), Dr. Julia von Oettingen, (Montreal Children’s Hospital; McGill University) and Dr. Ian Zenlea, (Trillium Health Partners; University of Toronto).

Summary

Although there have been many advances in diabetes care since insulin was discovered 100 years ago, youth with diabetes continue to have a higher risk of other health problems, a lower quality of life, and a shorter life span than their peers without diabetes. This health gap is likely in part due to suboptimal access to and delivery of their diabetes care, which is worse in disadvantaged populations across Canada. This project will develop strategies to address these gaps.

The CAnadian PediAtric diabetes ConsortIum (CAPACIty) is a network of 15 childhood diabetes centers from across Canada. They are partnering with patients/families and health care professionals to jointly design and develop a Canada-wide childhood diabetes registry and research platform. The registry will enable them to improve diabetes care and health outcomes for Canadian youth through comparison of diabetes care quality and outcomes between Canadian diabetes centers, quality improvement initiatives, patient-informed research initiatives across Canada, and successful advocacy work.

They anticipate that the CAPACIty registry will not only lead to better health outcomes but also serve as a powerful tool for governments and decision-makers to implement policy decisions that are driven by our data. Lastly, the patient advisory board will ensure better representation of youth with diabetes and their parents among provincial and national associations that advocate for people living with diabetes.

This is the first announcement of two of four grants total. The second two grants will be announced later this winter.

For more information on the JDRF-CIHR Partnership to Defeat Diabetes please visit: https://breakthrought1d.ca/research/jdrf-cihr-funded-projects/

JDRF Canada and Canada’s Stem Cell Network partner to launch National Fellowship Program in Type 1 Diabetes

November 15, 2021

November 15, 2021 (Ottawa/Toronto) JDRF Canada and Canada’s Stem Cell Network are pleased to announce the JDRF-SCN National Fellowship Program in Type 1 Diabetes, a new opportunity for high-calibre postdocs from across Canada with expertise in stem cells, regenerative medicine, immunology or related fields to join the JDRF Centre of Excellence at the University of British Columbia (UBC) to pursue research focused on treating and curing type 1 diabetes (T1D).

T1D is an autoimmune disease that affects the daily lives of approximately 300,000 Canadians. It occurs when the body’s immune system attacks and destroys the cells in the pancreas that make insulin. While 2021 marks the 100th anniversary of the discovery of insulin and the 60th anniversary of the discovery of stem cells, and despite much progress made to tackle this disease, T1D remains a tremendous economic and health burden for thousands of Canadians and their families.  

The new JDRF-SCN National Fellowship Program in Type 1 Diabetes aims to attract promising postdoctoral researchers to help accelerate Canadian research, develop talent and enhance Canada’s global leadership in T1D research.

“SCN has been a driver in the quest to find a cure for type 1 diabetes for the last 20 years,” said Cate Murray, SCN’s Executive Director and COO. “Our collaborative cross-Canada network has been leading the charge to develop life-changing therapies for this highly debilitating disease. SCN is excited to work with JDRF, a valued partner in this initiative.”

“We are delighted to be partnering with SCN to support postdoctoral fellowships through the JDRF Centre of Excellence at UBC launching this winter,” says Dave Prowten, President and CEO of JDRF Canada. “The Centre is an initiative focused on cure research with a unique and multidisciplinary training program that will give rise to future leaders in Canadian type 1 diabetes research.” 

Launching in January 2022, the Fellowship Program will award one yearlong fellowship per year through 2026, with a value of $60,000 CAD per year.

Anticipated timeline:

Launch of request for applications: January 14, 2022
Application deadline: April 15, 2022 at 17:00 ET
Funding decision: July 4, 2022
Latest fellowship start date in Vancouver: Sept 15, 2022

About the Stem Cell Network: The Stem Cell Network (SCN) is a national not-for-profit organization that supports three main objectives: stem cell and regenerative medicine research; training the next generation of highly qualified personnel; and supporting the knowledge mobilization and transfer of stem cell and regenerative medicine research. From the lab to the clinic, our goal is to power science that will benefit Canadians. SCN was created in 2001. With support from the Government of Canada, the Network has grown from a few dozen labs to more than 196 world-class research groups, supporting 200+ research projects and 24 clinical trials. Since its inception, 21 biotech companies have been catalyzed and more than 4,000 highly qualified personnel have been trained. In 2021, the Government of Canada demonstrated its continuing trust and support in SCN with an investment of $45 million for the 2022–25 period.

About JDRF: JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our goal is to raise funds to support the most advanced international T1D research and progressively remove the impact of this disease from people’s lives – until we achieve a world without it. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure T1D. For more information, please visit j drf.c a.

For more details on the Fellowship Program, please contact: research@jdrf.ca; jdraper@stemcellnetwork.ca

JDRF Canada marks National Diabetes Awareness Month by launching new Monster Tamer Campaign

November 10, 2021

Toronto, ON — November 10, 2021 – JDRF Canada, the leading organization funding type 1 diabetes (T1D) research, is marking November and National Diabetes Awareness Month (NDAM) with a new Monster Tamer Campaign. T1D is an autoimmune disease that many have said can feel like living with a monster – a monster that requires you to make up to 300 life or death decisions every day about eating, activity, rest and more just to maintain blood sugar levels.

For over 100 years, we’ve been taming the T1D monster with tools like insulin, glucose monitors, and fast acting carbohydrates like juice boxes. But as we commemorate the 100th anniversary of the discovery of insulin here in Toronto, we recognize that now is the time to move beyond insulin and accelerate research towards cures and finally defeat the T1D monster, once and for all.

“For most children, a juice box is something that they have in their lunch for school, but for those living with T1D it is so much more,” says JDRF President and CEO Dave Prowten. “A juice box can be an emergency tool that helps regulate blood sugar and can halt the symptoms of hypoglycemia (low blood sugar) that can make those living with T1D sick, and even lead to more serious repercussions. That is why with our new campaign we have made the connection to juice boxes being a “monster tamer”, and our goal this NDAM is to raise awareness of how challenging living with T1D really is.”

Throughout November, JDRF is encouraging Canadians impacted by T1D to share their stories by describing their personal T1D monsters on social media using the hashtag #MyT1DMonster or by submitting them online at breakthrought1d.ca/t1dmonster.

Additionally, to mark World Diabetes Day on November 14, important landmarks and public buildings will be lit in blue across the country, including Toronto’s CN Tower, the Calgary Tower and British Columbia’s Canada Place, along with numerous City Halls. World Diabetes Day is recognized globally to raise awareness for the disease and falls on the birthday of Sir Frederick Banting, who discovered insulin along with Charles Best in 1921.For more information about JDRF’s Monster Tamer campaign visit breakthrought1d.ca/T1Dmonster.

About JDRF

Media contact:

Vanessa Parent
National Bilingual Marketing and Communications Specialist
JDRF Canada
514-262-6346
vparent@jdrf.ca

JDRF and Sun Life challenge corporate Canada to move work aside and move for a cure

October 4, 2021

The Sun Life Ride to Defeat Diabetes for JDRF invites people across Canada to raise funds to support type 1 diabetes research

TORONTO, Oct 5, 2021 – One of Canada’s top fundraising events will be taking place on October 7, 2021. For the second straight year, the Sun Life Ride to Defeat Diabetes for JDRF will be a virtual, high-energy corporate fitness event, bringing out the friendly, competitive spirit of Canadians. The event will offer a fun corporate team building experience – with the goal of turning type 1 diabetes (T1D) into type none.

This year is particularly special as we commemorate the 100^th anniversary of the discovery of insulin. While a historic milestone that changed the outcomes for millions of people with diabetes, it remains the only treatment for the disease and is not a cure. That is why JDRF is continuing to pursue the most promising T1D research to move us beyond insulin towards cures.

Corporate Canada will move for a cure by spinning on a stationary bike, stretching with a yoga routine, or breaking a sweat at a fitness class during the hour-long virtual event. Participants will join their colleagues in an immersive experience featuring a dynamic opening show, industry fundraising challenges, networking lounges, sponsor booths and contests. Funds raised will help advance ground-breaking research that will make a positive difference for as many as 300,000 Canadians and their families touched by T1D.

“We are once again bringing the excitement and energy of our Ride to people’s homes and giving corporate Canada a unique way to come together to team build, enjoy a healthy break during the busy workday, and most importantly, bring us closer to a cure for T1D,” said Dave Prowten, President and CEO of JDRF Canada. “We are relying on the power of corporate Canada to help reach our $1.8 million goal, which will help us to accelerate the pace of T1D research.”

Sun Life has been a proud supporter of the Ride since 2017, and in 2019 they became the national title sponsor. Sun Life is committed to supporting the over 422 million people worldwide living with the disease.

“Millions of people are living with or at risk of developing diabetes. The discovery of insulin 100 years ago drastically changed the treatment, but there is still no cure. That is why the Sun Life Ride to Defeat Diabetes is so important. The Ride raises funds for type 1 diabetes research, innovation and care initiatives,” said Jacques Goulet, President, Sun Life Canada. “Supporting organizations like JDRF is one way we are making a difference for people affected by diabetes and helping them live healthier lives. Since 2012, we have proudly committed more than $38 million globally in support of diabetes awareness, prevention, care and research initiatives.”

About JDRF Canada

JDRF is the leading charitable organization funding type 1 diabetes (T1D) research. Our goal is to raise funds to support the most advanced international T1D research and progressively remove the impact of this disease from people’s lives – until we achieve a world without T1D. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure type 1 diabetes. JDRF is the largest charitable funder of and advocate for research to cure, prevent and treat T1D in the world. For more information, please visit breakthrought1d.ca.

Sun Life in the community
At Sun Life, we are committed to building sustainable, healthier communities for life. Community wellness is an important part of our sustainability commitment, and we believe that by actively supporting the communities in which we live and work, we can help build a positive environment for our clients, employees, advisors, and shareholders. Our philanthropic support focuses on health, with an emphasis on diabetes awareness, prevention, and care initiatives; and mental health, supporting programs and organizations with a focus on building resilience and coping skills.

We also partner with sports properties in key markets to further our commitment to healthy and active living. Our employees and advisors take great pride in volunteering close to 12,000 hours each year and contribute to making life brighter for individuals and families across Canada.

For more information:

Vanessa Parent
Bilingual Marketing & Communications Specialist at JDRF Canada
C: (647) 459-7881
vparent@jdrf.ca

Filling the Forgotten Gaps in Care – JDRF Canada Launches Strategy for Mental Health and Type 1 Diabetes

September 28, 2021

TORONTO, September 28, 2021 — 2021 marks the 100th anniversary of the discovery of insulin in Toronto. Earlier this year, in honour of this anniversary, JDRF Canada, the largest charitable funder of type 1 diabetes (T1D) research in Canada, launched its $100M Campaign to Accelerate to build upon a long legacy of outstanding Canadian diabetes research, accelerating towards cures and improving the lives of those living with T1D. Today, JDRF Canada is launching a key pillar of its $100M Campaign to Accelerate and announcing a $2M fundraising campaign to support the development of its first mental health strategy.

T1D is an autoimmune disease that can be diagnosed at any age, but frequently presents in childhood. People living with T1D must follow a strict lifelong treatment plan that includes constant blood sugar monitoring, counting carbohydrates and taking insulin multiple times a day to stay alive. T1D can also affect a person’s emotional, social, and behavioural wellbeing throughout their lifetime, known collectively as psychosocial health. For example, one in five youth with T1D suffer from anxiety and, compared to those without the condition, people with diabetes are more likely to experience depression or develop an eating disorder.

“Mental health needs to be a larger part of care, especially for teens with diabetes. There is so much pressure socially, academically and hormonally and it’s hard to find anyone who understands the difficulty of managing diabetes on top of all of that”. Jenna, JDRF Youth Ambassador, diagnosed with T1D at age 12.

Traditional care of T1D primarily focuses on glucose control and mental health challenges of those living with the condition are often overlooked, which can contribute to poor overall health outcomes.

“Mental health challenges together represent one of the most pervasive health issues affecting Canadians today. When you add a chronic condition like T1D, feelings of anxiety, stress and depression are often amplified, which can negatively affect physical health,” says Dr. Sarah Linklater, Chief Scientific Officer of JDRF Canada. “With a clear indication of the mental health strain this disease has on people living with T1D and the obvious gaps in care, it’s time to take action and that’s why we are raising $2M and launching our first mental health strategy.”

JDRF Canada’s mental health strategy will initially include five areas of focus: funding research to test psychosocial interventions, providing education about psychosocial issues in diabetes to health care providers, supporting postdoctoral fellowships for clinical psychologists in training, providing support and resources for people living with T1D, and developing a virtual training program about diabetes for registered mental health care providers. Impact in all of these areas will be amplified through partnerships with various diabetes and mental health organizations, some of which will extend the reach of these programs to people living with type 2 diabetes.

With the help of donors and our initial partners including Brain Canada, BD, iA Financial Group, Canucks for Kids and The Leona M. and Harry B. Helmsley Charitable Trust, JDRF is well-positioned to take the lead on addressing gaps in care and tackling one of the most pervasive health issues facing Canadians with diabetes today. Together, we will provide a unified approach to helping families across Canada cope with all aspects of T1D.

About JDRF Canada

JDRF is the leading global organization funding type 1 diabetes research. Our goal is to raise funds to support the most advanced international type 1 diabetes research and progressively remove the impact of this disease from people’s lives – until we achieve a world without type 1 diabetes. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure type 1 diabetes. JDRF is the largest charitable funder of and advocate for research to cure, prevent and treat T1D in the world. For more information, please visit j drf.c a.

For more information:

Vanessa Parent
Bilingual Marketing & Communications Specialist at JDRF Canada
C: (647) 459-7881
vparent@jdrf.ca